Abstract
Chemical inhibitors of cyclin-dependent kinases (CDKs) have a great therapeutic potential against various proliferative and neurodegenerative disorders. Intensive screening of a combinatorial chemistry library of 2,6,9-trisubstituted purines has led to the identification of purvalanol, one of the most potent and selective CDK inhibitors to date. In preliminary studies, this compound demonstrates definite anti-mitotic properties, consistent with its nanomolar range efficiency towards purified CDK1 and CDK2. However, the actual intracellular targets of purvalanol remain to be identified, and a method for the determination of its in vivo selectivity was developed. In this technique, cell extracts were screened for purvalanol-interacting proteins by affinity chromatography on immobilized inhibitor. In addition to CDK1, p42/p44 MAPK were found to be two major purvalanol-interacting proteins in five different mammalian cell lines (CCL39, PC12, HBL100, MCF-7 and Jurkat cells), suggesting the generality of the purvalanol/p42/p44 MAPK interaction. The Chinese hamster lung fibroblast cell line CCL39 was used as a model to investigate the anti-proliferative properties of purvalanol. The compound inhibited cell growth with a GI50 value of 2.5 μM and induced a G2/M block when added to exponentially growing cells. It did not appear to trigger massive activation of caspase. We next tested whether CDKs and p42/p44 MAPK were actually targeted by the compound in vivo. p42/p44 MAPK activity was visualized using an Elk–Gal4 luciferase reporter system and CDK1 activity was detected by the phosphonucleolin level. When cells were treated with purvalanol, p42/p44 MAPK and CDK1 activities were inhibited in a dose-dependent manner. Furthermore, purvalanol inhibited the nuclear accumulation of p42/p44 MAPK, an event dependent on the catalytic activity of these kinases. We conclude that the anti-proliferative properties of purvalanol are mediated by inhibition of both p42/p44 MAPK and CDKs. These observations highlight the potency of moderate selectivity compounds and encourage the search for new therapeutics which simultaneously target distinct but relevant pathways of cell proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant BT, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble MEM, Sausville EA, Schultz R, Yu W . 2000 J. Med. Chem. 43: 2797–2804
Barvian M, Boschelli DH, Cossrow J, Dobrusin E, Fattaey A, Fritsch A, Fry D, Harvey P, Keller P, Garrett M, La F, Leopold W, McNamara D, Quin M, Trumpp-Kallmeyer S, Toogood P, Wu Z, Zhang E . 2000 J. Med. Chem. 43: 4606–4613
Borgne A, Meijer L . 1996 J. Biol. Chem. 271: 27847–27854
Brooks EE, Gray NS, Joly A, Kerwar SS, Lum R, Mackman RL, Norman TC, Rosete J, Rowe M, Schow SR, Schultz PG, Wang X, Wick MM, Shiffman D . 1997 J. Biol. Chem. 272: 29207–29211
Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J . 1999 EMBO J. 18: 664–674
Carini DJ, Kaltenbach RF, Liu J, Benfield PA, Boylan J, Boisclair M, Brizuela L, Burton CR, Cox S, Grafstrom R, Harrison BA, Harrison K, Akamike E, Markwalder JA, Nakano Y, Seitz SP, Sharp DM, Trainor GL, Sielecki TM . 2001 Bioorg. Med. Chem. Lett. 11: 2209–2211
Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG . 1999 Chem. Biol. 6: 361–375
Clare PM, Poorman RA, Kelley LC, Watenpaugh KD, Bannow CA, Leach KL . 2001 J. Biol. Chem. 276: 48292–48299
Damiens E, Meijer L . 2000 Pathol. Biol. 48: 340–351
Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF . 2001 Science 291: 134–137
de Azevedo WF, Leclerc S, Miejer L, Havlicek L, Strnad M, Kim SH . 1997 Eur. J. Biochem. 243: 518–526
Dranovsky A, Vincent I, Gregori L, Schwarzman A, Colflesh D, Enghild J, Strittmatter W, Davies P, Goldgaber D . 2001 Neurobiol. Aging 22: 517–528
Dreyer MK, Borcherding DR, Dumont JA, Peet NP, Tsay JT, Wright PS, Bitonti AJ, Shen J, Kim SH . 2001 J. Med. Chem. 44: 524–530
Dunphy WG . 1997 Meth. Enzymol. 283: 1–678
Edelmann HM, Kuhne C, Petritsch C, Ballou LM . 1996 J. Biol. Chem. 271: 963–971
Fischer PM, Lane DP . 2000 Curr. Med. Chem. 7: 1213–1245
Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD . 2001 J. Biol. Chem. 276: 16617–16623
Garrett MD, Fattaey A . 1999 Curr. Opin. Genet. Dev. 9: 104–111
Gille H, Sharrocks AD, Shaw PE . 1992 Nature 358: 414–417
Gray N, Detivaud L, Doerig C, Meijer L . 1999 Curr. Med. Chem. 6: 859–875
Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, Leclerc S, Meijer L, Kim SH, Lockhard DJ, Schultz PG . 1998 Science 281: 533–538
Hardcastle IR, Golding BT, Griffin RJ . 2002 Annu. Rev. Pharmacol. Toxicol. 42: 325–348
Herrera R, Sebolt-Leopold JS . 2002 Trends Mol. Med 8: S27–S31
Hoebeke J, Van Nijen G, De Brabander M . 1976 Biochem. Biophys. Res. Commun. 69: 319–324
Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L . 1999 Nat. Cell Biol. 1: 60–67
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M . 1999 Oncogene 18: 813–822
Janknecht R, Ernst WH, Pingoud V, Nordheim A . 1993 EMBO J. 12: 5097–5104
Jeong HW, Kim MRR, Son KH, Han MY, Ha JH, Garnier M, Meijer L, Kwon BM . 2000 Biorg. Med. Chem. Lett. 10: 1819–1822
Kaiser A, Nishi K, Gorin FA, Walsh DA, Bradbury EM, Schnier JB . 2001 Arch. Biochem. Biophys. 386: 179–187
Kaubisch A, Schwartz GK . 2000 Cancer J. 6: 192–212
Keenan SM, Bellone C, Baldassare JJX . 2001 J. Biol. Chem. 276: 22404–22409
Kent LL, Hull-Campbell NE, Lau T, Wu JC, Thompson SA, Nori M . 1999 Biochem. Biophys. Res. Commun. 260: 768–774
Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tamaka N, Okuyama A . 1993 Oncogene 8: 2425–2432
Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, Fergusson D, Mottram J, Soete M, Dubremetz JF, Le Roch K, Doerig C, Schultz P, Meijer L . 2000 Chem. Biol. 7: 411–422
Knockaert M, Greengard P, Meijer L . 2002a Trends Pharmacol. Sci. (in press)
Knockaert M, Wieking K, Schmitt S, Leost M, Mottram J, Kunick C, Meijer L . 2002b J. Biol. Chem. 277: 25493–25501
Lane ME, Uu B, Rice A, Lipson KE, Liang C, Sun L, Tang C, McMahon G, Pestell RG, Wadler S . 2001 Cancer Res. 61: 6170–6177
Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L . 2001 J. Biol. Chem. 276: 251–260
Legraverend M, Noble M, Tunnah P, Ducrot P, Ludwig O, Leclerc S, Grierson DS, Meijer L, Endicott J . 2000 J. Med. Chem. 43: 1282–1292
Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A, Pouyssegur J . 1993 J. Cell Biol. 122: 1079–1088
Lenormand P, McMahon M, Pouyssegur J . 1996 J. Biol. Chem. 271: 15762–15768
Lenormand P, Brondello JM, Brunet A, Pouyssegur J . 1998 J. Cell Biol. 142: 625–633
Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL, Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C, Meijer L . 2000 Eur. J. Biochem. 267: 5983–5994
Losiewicz MD, Carison BA, Kaur G, Sausville EA, Worland PJ . 1994 Biochem. Biophys. Res. Commun. 201: 589–595
Malumbres M, Ortega S, Barbacid M . 2000 Biol. Chem. 381: 827–838
Mani S, Wang C, Wu K, Francis R, Pestell R . 2000 Expert Opin. Investig. Drugs 9: 1849–1870
Marais R, Wynne J, Treisman R . 1993 Cell 73: 381–393
Meijer L . 2000 Drug resist Updat 3: 83–88
Meijer L, Kim SH . 1997 Methods Enzymol. 283: 113–128
Meijer L, Pondaven P . 1988 Exp. Cell Res. 174: 116–129
Meijer L, Borgne A, Muler O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP . 1997 Eur. J. Biochem. 243: 527–536
Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J, Mandelkow EM, Kim SH, Pettit GR . 2000 Chem. Biol. 7: 51–63
Meloche S, Pages G, Pouyssegur J . 1992 Mol. Biol. Cell 3: 63–71
Milanini J, Vinals F, Pouyssegur J, Pages G . 1998 J. Biol. Chem. 273: 18165–18172
Morgan DO . 1997 Annu. Rev. Cell. Dev. Biol. 13: 261–291
Neant I, Guerrier P . 1988 Exp. Cell Res. 176: 68–79
Nugiel DA, Etzkorn AM, Vidwans A, Benfield PA, Boisclair M, Burton CR, Cox S, Czerniak PM, Doleniak D, Seitz SP . 2001 J. Med. Chem. 44: 1334–1336
Oikonomakos NG, Schnier JB, Zographos SE, Skamnaki VT, Tsitsanou KE, Johnson LN . 2000 J. Biol. Chem. 275: 34566–34573
Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J . 1993 Proc. Natl. Acad. Sci. USA 90: 8319–8323
Park SG, Cheon JY, Lee YH, Park JS, Lee KY, Lee CH, Lee SK . 1996 Mol. Cells 6: 679–683
Parker CW, Entsch B, Letham DS . 1986 Phytochemistry 25: 303–310
Pavletich NP . 1999 J. Mol. Biol. 287: 821–828
Rialet V, Meijer L . 1991 Anticancer Res. 11: 1581–1590
Rosania GR, Chang T . 2000 Exp. Opin. Ther. Patents 10: 1–16
Rosania GR, Merlie Jr J, Gray N, Chang YT, Schultz PG, Heald R . 1999 Proc. Natl. Acad. Sci. USA 96: 4797–4802
Samuels ML, Weber MJ, Bishop M, McMahon M . 1993 Mol. Cell. Biol. 13: 6241–6252
Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malin M, Gray N, Schaffer PA . 2002 J. Virol. 76: 7874–7882
Schnier JB, Kaur G, Kaiser A, Stinson SF, Sausville EA, Gardner J, Nishi K, Bradbury EM, Senderowicz AM . 1999 FEBS Lett. 454: 100–104
Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, Meijer L, Kunick C . 1999 J. Med. Chem. 42: 2909–2919
Schultze-Gahmen U, Brandsen J, Jones HD, Morgan DO, Meijer L, Vesely J, Kim SH . 1995 Proteins – Struct. Funct. Genet. 22: 378–391
Sebolt-Leopold JS . 2000 Oncogene 19: 6594–6599
Senderowicz AM, Sausville EA . 2000 J. Natl. Cancer Inst. 92: 376–387
Shapiro PS, Vaisberg E, Hunt AJ, Tolwinski NS, Whalen AM, McIntosh JR, Ahn NG . 1998 J. Cell Biol. 142: 1533–1545
Sherwood SW, Sheridan JP, Schimke RT . 1994 Exp. Cell Growth Differ. 215: 373–379
Shewchuk L, Hassell A, Wisely B, Rocque W, Holmes W, Veal J, Kuyper LF . 2000 J. Med. Chem. 43: 133–138
Shum PW, Peet NP, Weintraub PM, Le TB, Zhao Z, Barbone F, Cashman B, Tsay J, Dwyer S, Loos PC, Powers EA, Kropp K, Wright PS, Bitonti A, Dumont J, Borcherding DR . 2001 Nucleosides Nucleotides Nucleic Acids 20: 1067–1078
Sielecki TM, Boylan JF, Benfield PA, Trainor GL . 2000 J. Med. Chem. 43: 118
Sielecki TM, Johnson TL, Liu J, Muckelbauer JK, Grafstrom RH, Cox S, Boylan J, Burton CR, Chen H, Smallwood A, Chang CH, Boisclair M, Benfield PA, Traimor GL, Seitz SP . 2001 Biorganic Medic. Chem. Lett. 11: 1157–1160
Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B . 2000 Biochem. Biophys. Res. Commun. 275: 877–884
Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B . 2001 J. Natl. Cancer Inst. 21: 436–446
Toogood PL . 2001 Med. Res. Rev. 21: 487–498
Urbani L, Sherwood SW, Schimke RT . 1995 Exp. Cell Res. 219: 159–168
Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S, Meijer L . 1994 Eur. J. Biochem. 224: 771–786
Villerbu N, Gaben AM, Redeuilh G, Mester J . 2002 Int. J. Cancer 97: 761–769
Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang FM, McCubrey JA . 2000 Pharmacol. Ther 88: 229–279
Wright JH, Munar E, Jameson DR, Andreassen PR, Margolis RL, Seger R, Krebs EG . 1999 Proc. Natl. Acad. Sci. USA 96: 11335–11340
Yu C, Wang S, Dent P, Grant S . 2001 Mol. Pharmacol. 60: 143–154
Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA . 1999 Cancer Res. 59: 2566–2569
Zimmermann J . 1995 Pharmacologically active pyrimidine derivatives and processes for the preparation thereof. PCT Ciba-Geigy, WO 95/09853
Acknowledgements
We would like to thank our colleagues for providing reagents and help: Eve Damiens and Dominique Marie for their assistance in FACS analysis, Peter Davis for providing the TG3 antibody, Dr M Yamashita for providing the Cyclin Bcdc13 antibody and Bruce Cagnol for PARP cleavage analysis. We are grateful to Sandrine Boulben for her help with the Western blot quantification. This research was also supported by grants from the ‘Association pour la Recherche sur le Cancer’ (ARC 5343 & ARC5732) (L Meijer) and the ‘Conseil Régional de Bretagne’ (L Meijer).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Knockaert, M., Lenormand, P., Gray, N. et al. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene 21, 6413–6424 (2002). https://doi.org/10.1038/sj.onc.1205908
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205908
Keywords
This article is cited by
-
Affinity purification in target identification: the specificity challenge
Archives of Pharmacal Research (2015)
-
Inhibition of polyamine oxidase prevented cyclin-dependent kinase inhibitor-induced apoptosis in HCT 116 colon carcinoma cells
Apoptosis (2013)
-
Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro
Angiogenesis (2010)
-
Target profiling of small molecules by chemical proteomics
Nature Chemical Biology (2009)
-
Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo
BMC Cancer (2008)